DRTS — Alpha Tau Medical Ltd.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1871321 ·
Last close
$9.61
Market Cap
$868.03M
52W High
$11.62
52W Low
$6.35
ADV30
1,074,359
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -13,313,000 | -22,939,000 | 108,773,000 | 4,636,000 | 39,421,000 |
| Dec 2025 | 0 | — | -12,602,000 | -12,136,000 | 105,652,000 | 12,202,000 | 28,553,000 |
| Sep 2025 | 0 | — | -10,730,000 | -11,686,000 | 104,694,000 | 3,329,000 | 27,110,000 |
| Jun 2025 | 0 | — | -9,648,000 | -10,114,000 | 110,954,000 | 11,703,000 | 24,331,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-190,136,000
Inventory
—
Receivables
$336,000
ST Investments
$60,924,000
EBIT TTM
$-42,159,000
Pretax Income TTM
$-42,506,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -42,288,000 | -42,627,000 | 105,652,000 | 28,553,000 | — | -26,681,000 |
| Dec 2024 | 0 | -36,042,000 | -31,750,000 | 86,204,000 | 23,538,000 | — | -19,783,000 |
| Dec 2023 | 0 | -35,680,000 | -29,157,000 | 107,388,000 | 22,913,000 | — | -17,958,000 |
| Dec 2022 | 0 | -32,136,000 | -33,762,000 | 120,149,000 | 14,492,000 | — | -23,879,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.51
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $9.61 · call volume: 212 · put volume: 301
Expected Move to 2026-11-20:
±$4.40
(45.79%) —
implied range
$5.21 –
$14.01
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STVN | Stevanato Group S.p.A. | $848.05M | $17.06 | — |
| AVR | Anteris Technologies Global Corp. | $924.75M | $9.50 | — |
| INMD | InMode Ltd. | $812.40M | $13.36 | — |
| CNMD | CONMED Corp | $966.81M | $32.11 | — |
| AORT | ARTIVION, INC. | $1.03B | $21.20 | — |
News headlines (Yahoo Finance, 1h cache)
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
2026-06-11 12:30 · Yahoo
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing
2026-06-03 14:52 · Yahoo
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
2026-06-03 12:30 · Yahoo
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
2026-06-01 13:00 · Yahoo
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
2026-05-29 13:03 · Yahoo
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-18 20:01 · Yahoo
Alpha Tau to Participate in May Investor Conferences
2026-05-18 12:30 · Yahoo
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
2026-05-11 14:07 · Yahoo
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Obs
2026-05-11 11:00 · Yahoo
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
2026-05-08 13:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.